Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17889432 | 0.92 | PI4KB (0.59) | PI4KBKCNH2 | |
| SCHEMBL17889322 | 0.90 | PI4KB (0.76) | PI4KBKCNH2ALDH1A1GAAMAPK1 | |
| SCHEMBL17889410 | 0.87 | PI4KB (0.70) | PI4KBKCNH2 | |
| SCHEMBL17889378 | 0.85 | PI4KB (0.76) | PI4KBKCNH2ALDH1A1GAAMAPK1 | |
| SCHEMBL17889500 | 0.85 | PI4KB (0.68) | PI4KBKCNH2TRPV1 | |
| SCHEMBL17889429 | 0.83 | PI4KB (0.60) | PI4KBKCNH2MAPK1 | |
| SCHEMBL17889505 | 0.83 | PI4KB (0.62) | PI4KBKCNH2 | |
| SCHEMBL17889468 | 0.83 | PI4KB (1.00) | PI4KBKCNH2ALDH1A1GAAMAPK1 | |
| SCHEMBL17889470 | 0.83 | PI4KB (1.00) | PI4KBKCNH2ALDH1A1GAAMAPK1 | |
| SCHEMBL17889425 | 0.83 | PI4KB (0.78) | PI4KBKCNH2ALDH1A1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | claimed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | claimed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | claimed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | PI4KB 275/4885KCNH2 3599/4885GSK3B 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.